iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-604-6029414
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable
iCo Therapeutics (CVE:ICO) Frequently Asked Questions
What is iCo Therapeutics' stock symbol?
iCo Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ICO."
When is iCo Therapeutics' next earnings date?
Has iCo Therapeutics been receiving favorable news coverage?
News stories about ICO stock have been trending somewhat negative on Monday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCo Therapeutics earned a daily sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for iCo Therapeutics.
Who are some of iCo Therapeutics' key competitors?
Some companies that are related to iCo Therapeutics include Helix Biopharma (HBP), Imugene (IMU), Tiziana Life Sciences (TILS), Ampio Pharmaceuticals (AMPE), Orgenesis (ORGS), Circassia Pharmaceuticals (CIR), Equillium (EQ), Pediapharm (PDP), Medicure (MPH), ReNeuron Group (RENE), Promis Neurosciences (PMN), AquaBounty Technologies (AQB), Mereo BioPharma Group (MPH), Orthocell (OCC) and IntelGenx Technologies (IGX).
What other stocks do shareholders of iCo Therapeutics own?
Who are iCo Therapeutics' key executives?
iCo Therapeutics' management team includes the folowing people:
- Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)
- Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)
- Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63)
How do I buy shares of iCo Therapeutics?
Shares of ICO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is iCo Therapeutics' stock price today?
One share of ICO stock can currently be purchased for approximately C$0.12.
How big of a company is iCo Therapeutics?
What is iCo Therapeutics' official website?
How can I contact iCo Therapeutics?
iCo Therapeutics' mailing address is 760-777 Hornby St, VANCOUVER, BC V6Z 1S4, Canada. The company can be reached via phone at +1-604-6029414.
MarketBeat Community Rating for iCo Therapeutics (CVE ICO)
MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICO will underperform the S&P 500 over the long term. You may vote once every thirty days.
